MannKind Corporation (MNKD) Q2 2026 Earnings Call Transcript
MannKind Corporation (MNKD) Q2 2026 Earnings Call Transcript
Seeking Alpha8/6/2026Neutral
MNKD
MannKind CorpNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$1.32B
P/E Ratio
—
EPS
$-0.15
Beta
1.10
52W High
$6.51
52W Low
$2.23
50-Day MA
$3.91
200-Day MA
$4.30
Dividend Yield
—
Profit Margin
-11.10%
Forward P/E
117.65
PEG Ratio
4.39
About MannKind Corp
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutics for endocrine and orphan lung diseases in the United States. The company is headquartered in Westlake Village, California.
Fundamentals
| Revenue (TTM) | $393.63M |
| Gross Profit (TTM) | $296.74M |
| EBITDA | $28.14M |
| Operating Margin | -0.76% |
| Return on Equity | 0.00% |
| Return on Assets | 0.79% |
| Revenue/Share (TTM) | $1.42 |
| Book Value | $-0.17 |
| Price-to-Book | 187.85 |
| Price-to-Sales (TTM) | 3.36 |
| EV/Revenue | 3.916 |
| EV/EBITDA | 75.66 |
| Quarterly Earnings Growth (YoY) | -34.90% |
| Quarterly Revenue Growth (YoY) | 42.90% |
| Shares Outstanding | $321.54M |
| Float | $315.45M |
| % Insiders | 1.48% |
| % Institutions | 58.18% |
Historical Volatility
HV 10-Day
72.16%
HV 20-Day
63.46%
HV 30-Day
67.53%
HV 60-Day
62.82%
HV Rank
—
Volatility is currently expanding
Analyst Ratings
Consensus ($8.09 target)
7
Buy1
HoldLatest News
MannKind Q2 Earnings Call Highlights
MannKind NASDAQ: MNKD reported second-quarter revenue of $109.4 million, up 43% from the prior-year period, as growth in its commercial products and collaboration revenue helped offset increased spending tied to product launches and development programs.
MarketBeat8/6/2026Positive
MannKind Corporation (MNKD) Discusses Phase 1b Results and Clinical Progress of Nintedanib DPI for IPF Transcript
MannKind Corporation (MNKD) Discusses Phase 1b Results and Clinical Progress of Nintedanib DPI for IPF Transcript
Seeking Alpha7/30/2026Neutral
MannKind injection helps heart failure patients avoid ER infusions
We also report on an experimental diagnostic approach that can detect tuberculosis exposure and infection at an earlier stage than current methods.
Reuters7/29/2026Positive
MannKind Reports Positive Phase 1b INFLO-1 Results, Demonstrating Safety and Tolerability of Nintedanib DPI and Clinical Validation of Its DPI Technology in IPF
MNKD Reports Positive Phase 1b INFLO-1 Results, Demonstrating Safety & Tolerability of Nintedanib DPI and Clinical Validation of Its DPI Technology in IPF
GlobeNewsWire7/29/2026Neutral
MannKind to Report Second Quarter Financial Results and Host Conference Call on August 5, 2026
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., July 28, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), today announced that the Company will report second quarter 2026 financial results after market close on Wednesday, August 5, 2026.
GlobeNewsWire7/28/2026Neutral
MannKind Corporation (MNKD) Discusses FDA Approval of Furoscix ReadyFlow for IV-Equivalent Diuretic Therapy in Fluid Overload Transcript
MannKind Corporation (MNKD) Discusses FDA Approval of Furoscix ReadyFlow for IV-Equivalent Diuretic Therapy in Fluid Overload Transcript
Seeking Alpha7/24/2026Neutral
MannKind Wins FDA Approval for Furoscix ReadyFlow, Secures $50M PIPE
MannKind NASDAQ: MNKD said the U.S. Food and Drug Administration approved Furoscix ReadyFlow, an auto-injector designed to deliver an 80-milligram dose of subcutaneous furosemide in five to 10 seconds for the management of fluid overload.
MarketBeat7/24/2026Positive
MannKind Announces $50 Million Private Placement
DANBURY, Conn. and WESTLAKE VILLAGE, Calif.
GlobeNewsWire7/24/2026Neutral
MannKind Announces FDA Approval of Furoscix ReadyFlow™, the First and Only Autoinjector Delivering IV-Equivalent Diuretic Therapy for the Treatment of Edema in Adults with Heart Failure or Chronic Kidney Disease
MannKind announces FDA approval of Furoscix ReadyFlow™, the first & only autoinjector delivering IV-equivalent diuretic therapy for the treatment of edema
GlobeNewsWire7/24/2026Neutral
Turn research into an automated options-selling system
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on MNKD and any ticker you trade — then tracks every position and per-strategy win rate.
More HEALTHCARE Stocks
Data last updated: 8/10/2026